IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil

- May 8th, 2019

IntelGenx (TSXV:IGX, OTCQX:IGXT) has announced it has entered into a partnership with Aquestive Therapeutics (NASDAQ:AQST) to co-develop and commercialize Tadalafil oral films to treat erectile dysfunction. As quoted in the press release: Under the terms of the Agreement, IntelGenx and Aquestive will each grant to the other exclusive worldwide licenses to their respective intellectual property … Continued

IntelGenx (TSXV:IGX, OTCQX:IGXT) has announced it has entered into a partnership with Aquestive Therapeutics (NASDAQ:AQST) to co-develop and commercialize Tadalafil oral films to treat erectile dysfunction.

As quoted in the press release:

Under the terms of the Agreement, IntelGenx and Aquestive will each grant to the other exclusive worldwide licenses to their respective intellectual property relating to tadalafil oral film formulation and manufacturing. The companies will jointly undertake further co-development and commercialization of Tadalafil oral film products, and will equally share (50/50) net profits from worldwide product sales. In connection with the Agreement, Aquestive has also granted a non-exclusive, royalty bearing U.S. license to any of its intellectual property that may relate to the formulation and manufacturing of IntelGenx’s rizatriptan oral film product, RIZAPORT®. IntelGenx will pay Aquestive a royalty equal to 10% of all payments received by IntelGenx from third parties for U.S. product related milestones and sales

“We are pleased to collaborate with Aquestive given the synergy of our oral film technologies, particularly pertaining to the development and commercialization of tadalafil oral films,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “The launch of a partnered tadalafil oral film in the U.S. has the potential to bring a product to market sooner and maximize the commercial opportunity for IntelGenx, Aquestive, and our respective shareholders.”

“IntelGenx is a natural partner for our tadalafil oral film program,” said Dan Barber, Chief Operating Officer of Aquestive. “This partnership will allow us to continue to stay focused on advancing our commercial portfolio and late stage CNS programs, while working with IntelGenx to realize the full potential for tadalafil oral film on a global basis. We are also pleased to provide access to our extensive intellectual property portfolio for IntelGenx’s RIZAPORT® product.”

Click here to read the full press release.

We found the top performing pharma stocks to watch this year

Find out more in our report
 

Leave a Reply

Your email address will not be published. Required fields are marked *